SMTI
Sanara MedTech Inc. NASDAQ Listed Apr 7, 1994$22.02
+3.77%
vs $21.22
Mkt Cap $201.8M
52w Low $16.05
30.0% of range
52w High $35.95
50d MA $20.70
200d MA $23.50
P/E (TTM)
-5.0x
EV/EBITDA
18.6x
P/B
32.0x
Debt/Equity
8.1x
ROE
-632.5%
P/FCF
87.9x
RSI (14)
46.50
ATR (14)
$1.42
Beta
1.10
50d MA
$20.70
200d MA
$23.50
Avg Volume
58.0K
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
1200 Summit Avenue · Fort Worth, TX 76102 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | 0.11 | 0.04 | -63.6% | 18.08 | +0.3% | -9.6% | +10.2% | -5.8% | +1.9% | -0.6% | — |
| Nov 12, 2025 | AMC | -0.24 | 0.09 | +137.5% | 21.11 | -0.5% | -7.1% | +9.8% | -2.2% | -0.8% | -8.8% | — |
| Aug 13, 2025 | AMC | -0.33 | -0.23 | +30.3% | 31.92 | -0.7% | -4.8% | -2.4% | +6.4% | -2.3% | -0.4% | — |
| May 14, 2025 | AMC | -0.31 | -0.41 | -32.3% | 31.30 | +2.1% | -1.3% | +2.0% | -1.0% | -0.4% | -0.1% | — |
| Mar 25, 2025 | AMC | -0.19 | -0.18 | +5.3% | 31.20 | +1.3% | -5.0% | +5.4% | -3.3% | +2.3% | -1.6% | — |
| Nov 12, 2024 | AMC | -0.62 | -0.34 | +45.2% | 34.60 | +2.6% | +7.6% | -3.3% | -3.8% | +2.1% | +4.5% | — |
| Aug 12, 2024 | AMC | -0.21 | -0.41 | -95.2% | 27.83 | +1.5% | +15.1% | +2.1% | +0.9% | -1.8% | +1.0% | — |
| May 13, 2024 | AMC | -0.07 | -0.21 | -200.0% | 29.28 | -1.7% | +2.0% | +14.1% | -6.9% | -3.8% | +6.6% | — |
| Mar 25, 2024 | AMC | -0.13 | -0.03 | +76.9% | 36.25 | +1.4% | +1.4% | +1.5% | -0.8% | -1.5% | -3.4% | — |
| Nov 13, 2023 | AMC | -0.13 | -0.13 | +0.0% | 28.57 | -1.6% | +19.4% | -1.4% | -1.8% | +0.3% | -3.9% | — |
| Aug 14, 2023 | AMC | -0.13 | -0.22 | -69.2% | 44.58 | -3.5% | -9.7% | -1.3% | +0.1% | +0.0% | -1.9% | — |
| May 15, 2023 | AMC | -0.33 | -0.20 | +39.4% | 42.57 | -4.8% | -8.4% | -2.4% | +1.2% | -3.2% | -0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.75 | $21.75 | +0.0% | -2.3% | -2.1% | +2.8% | -1.5% | +4.5% |
| Nov 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.61 | $19.61 | +0.0% | +9.8% | -2.2% | -0.8% | -8.8% | +0.4% |
| Aug 18 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $29.68 | $30.35 | +2.3% | +6.4% | -2.3% | -0.4% | -0.7% | +11.2% |
| Aug 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.68 | $30.35 | +2.3% | +6.4% | -2.3% | -0.4% | -0.7% | +11.2% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.30 | $31.96 | +2.1% | -1.3% | +2.0% | -1.0% | -0.4% | -0.1% |
| Mar 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.20 | $31.60 | +1.3% | -5.0% | +5.4% | -3.3% | +2.3% | -1.6% |
| Mar 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.20 | $31.60 | +1.3% | -5.0% | +5.4% | -3.3% | +2.3% | -1.6% |
| Jan 23 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.72 | $38.04 | +0.8% | +1.1% | -2.6% | -1.2% | +2.6% | -3.5% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.72 | $38.04 | +0.8% | +1.1% | -2.6% | -1.2% | +2.6% | -3.5% |
| Jan 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $34.00 | $37.00 | +8.8% | +10.9% | +1.1% | -2.6% | -1.2% | +2.6% |
| May 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $29.86 | $29.88 | +0.1% | +14.1% | -6.9% | -3.8% | +6.6% | -3.1% |
| Mar 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.75 | $35.95 | -2.2% | +1.5% | -0.8% | -1.5% | -3.4% | -1.1% |
| Feb 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $34.97 | $36.26 | +3.7% | +4.7% | +5.5% | +4.1% | -1.8% | -4.0% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $34.10 | $34.90 | +2.3% | -1.4% | -1.8% | +0.3% | -3.9% | -4.1% |
| Sep 26 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $33.85 | $33.85 | +0.0% | -0.7% | -1.5% | -4.6% | -1.5% | -2.0% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $39.01 | $39.01 | +0.0% | -2.0% | -0.4% | -3.4% | -0.5% | +1.3% |
| Aug 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $39.71 | $41.45 | +4.4% | +0.1% | +0.0% | -1.9% | -2.0% | -0.4% |
| Jun 30 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.66 | $37.01 | +1.0% | +0.8% | -3.8% | +2.7% | +0.5% | -2.0% |
No insider trades available.
8-K
Sanara MedTech Inc. -- 8-K Filing
Jun 9
8-K
Unknown — 8-K Filing
Sanara MedTech's reaffirmed 2026 guidance signals management confidence in execution despite Q4 results, suggesting the stock may stabilize if investors believe growth targets are achievable.
Mar 24
8-K · 7.01
! Medium
Sanara MedTech Inc. -- 8-K 7.01: Regulation FD Disclosure
Sanara MedTech disclosed its 2026 priorities, strategy, and revenue expectations through a regulatory presentation, signaling management's strategic direction to investors for the upcoming fiscal year.
Mar 2
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 151,367 | $3M | New | Mar 2026 |
| 2 | Stonebridge Wealth Management, Llc | 136,899 | $2M | Added | Mar 2026 |
| 3 | Royal Bank Of Canada | 131,389 | $2M | Added | Mar 2026 |
| 4 | Morgan Stanley | 56,454 | $1M | Added | Dec 2025 |
| 5 | Marshall Wace, Llp | 76,282 | $1M | Added | Mar 2026 |
| 6 | Renaissance Technologies Llc | 64,680 | $1M | Added | Mar 2026 |
| 7 | Aqr Capital Management Llc | 39,938 | $686K | New | Mar 2026 |
| 8 | Northern Trust Corp | 33,256 | $571K | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 31,113 | $535K | Added | Mar 2026 |
| 10 | Bnp Paribas Financial Markets | 27,698 | $476K | Added | Mar 2026 |
| 11 | Qube Research & Technologies Ltd | 26,409 | $454K | New | Mar 2026 |
| 12 | Baird Financial Group, Inc. | 21,075 | $362K | Reduced | Mar 2026 |
| 13 | Jane Street Group, Llc | 15,217 | $355K | New | Dec 2025 |
| 14 | Salem Investment Counselors Inc | 19,200 | $330K | Added | Mar 2026 |
| 15 | Vanguard Portfolio Management Llc | 18,130 | $311K | New | Mar 2026 |
| 16 | Janney Montgomery Scott Llc | 17,530 | $301K | — | Mar 2026 |
| 17 | D.e. Shaw & Co | 16,323 | $280K | Added | Mar 2026 |
| 18 | Nuveen, Llc | 15,207 | $261K | New | Mar 2026 |
| 19 | Rockefeller Capital Management L.p. | 14,393 | $247K | Added | Mar 2026 |
| 20 | Point72 Asset Management | 10,335 | $178K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$201.8M
Enterprise Value
$219.3M
P/E (TTM)
-5.05x
Forward P/E
191.48x
PEG Ratio
-0.02x
P/B
32.02x
P/S
1.84x
P/FCF
87.87x
EV/EBITDA
18.57x
Shares Out
8.6M
Financials (TTM)
Revenue
$103.1M
Net Income
-$37.6M
EBITDA
$11.8M
Free Cash Flow
$2.2M
Op Cash Flow
$6.8M
EPS Basic
$-4.36
EPS Diluted
$-4.36
EPS Forward
$0.12
Gross Margin
90.1%
Op Margin
8.9%
Net Margin
-36.4%
Balance Sheet
Total Assets
$72.9M
Total Liab.
$67.0M
Total Equity
$5.9M
Cash
$16.6M
LT Debt
$46.0M
Book Value/Sh
$0.69
Debt/Equity
8.13x
Current Ratio
1.80
Quick Ratio
1.59
Returns & Growth
ROE
-632.5%
ROA
-51.5%
ROIC
16.7%
Rev Growth YoY
+19.0%
EPS Growth YoY
-282.5%
Price Returns
2W
+5.3%
1M
+20.0%
3M
+11.5%
6M
+8.9%
12M
-21.4%
Technicals
52W High
$35.95
52W Low
$16.05
50d MA
$20.70
200d MA
$23.50
RSI (14)
46.50
ATR (14)
$1.42
Beta
1.10
Avg Volume
58K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$32.00
High
$32.00
Low
$32.00
Median
$32.00
Data updated apr 27, 2026 2:00am
· Source: financialmodelingprep.com